AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
MediciNova Receives Buy Rating with $9.00 Price Target from D. Boral Capital Analyst Jason Kolbert.
ByAinvest
Friday, Jul 25, 2025 9:22 pm ET1min read
MediciNova (MNOV) receives a "Buy" rating and a $9.00 price target from analyst Jason Kolbert at D. Boral Capital. The rating and target are unchanged, indicating confidence in the company's current trajectory. Two analysts have a one-year price target average of $7.00, with an upside of 455.78% from the current price. The average brokerage recommendation is 2.0, indicating an "Outperform" status.
MediciNova Inc. (MNOV), a biopharmaceutical company focused on developing therapeutics for serious diseases, has received a positive outlook from analyst Jason Kolbert at D. Boral Capital. Kolbert maintains a "Buy" rating on the stock with a price target of $9.00, indicating confidence in the company's current trajectory and future prospects [2].The unchanged price target and rating suggest that Kolbert remains bullish on MediciNova's (MNOV) potential. The company's pipeline includes MN-166 (ibudilast) for neurological and other disorders, MN-001 (tipelukast) for fibrotic and other diseases, and MN-221 (bedoradrine) for acute exacerbation of asthma, among others [1].
Analysts' consensus indicates a one-year price target average of $7.00, with a high estimate of $9.00 and a low estimate of $5.00. This average target implies an upside of 455.78% from the current price of $1.26. Additionally, the average brokerage recommendation is 2.0, indicating an "Outperform" status [2].
MediciNova's recent earnings reports have shown promising results, with the company reporting earnings for the first quarter ended March 31, 2025. The company has also made significant strides in clinical trials and received patent approvals, further bolstering its market position [1].
Investors should closely monitor MediciNova's (MNOV) progress as the company continues to develop and commercialize its pipeline of innovative therapeutics. The positive analyst outlook and consistent performance indicators suggest that MediciNova remains a strong contender in the biotech sector.
References:
[1] https://www.marketscreener.com/quote/stock/MEDICINOVA-INC-38688/
[2] https://www.gurufocus.com/news/3001707/medicinova-mnov-receives-buy-rating-with-900-price-target-mnov-stock-news
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments

No comments yet